Senseonics Holdings, Inc. delivered strong Q4 2025 results, reporting net revenue of $14.3 million, a 72% increase from $8.3 million in the prior-year quarter.2021 Full-year revenue reached $35.3 million, up 57% year-over-year, driven by robust U.S. demand for the Eversense 365 continuous glucose monitoring system.
Key Operational Achievements
The company achieved 103% growth in new U.S. patients compared to 2024, fueled by effective direct-to-consumer marketing. Active prescribers expanded over 80%, and the Eon Care inserter network grew to 60 providers, handling 24% of U.S. insertions.20
Senseonics secured CE Mark approval for Eversense 365 in the European Union and plans launches in Germany, Italy, Spain, and Sweden. The firm also received FDA Investigational Device Exemption for the Gemini sensor, with first patients enrolled and trial completion expected in the second half of 2026.20
Integration of Eversense 365 with Sequel’s twiist Automated Insulin Delivery system rolled out across the U.S., enhancing options for type 1 diabetes patients. Senseonics executed agreements with Ascensia Diabetes Care to reclaim commercialization and distribution rights starting January 1, 2026.
Financial Performance
Fourth Quarter 2025
U.S. revenue hit $12.1 million, up from $6.2 million, while international revenue was $2.2 million. Gross profit rose to $7.7 million from $4.0 million, boosted by favorable 365-day product margins and lower manufacturing costs. R&D expenses fell to $8.8 million, but SG&A climbed to $19.8 million due to marketing and sales investments. Net loss stood at $20.8 million, or $0.46 per share.20
Full Year 2025
U.S. revenue totaled $27.9 million and international $7.4 million. Gross profit improved to $15.8 million from $0.5 million. R&D dropped to $31.6 million, while SG&A increased to $52.5 million. Net loss narrowed to $69.1 million, or $1.66 per share, from $78.6 million, or $2.50 per share. As of December 31, 2025, cash and equivalents stood at $94.3 million, with $35.3 million in debt.20
Executive Commentary
Tim Goodnow, President and CEO, highlighted the company’s transformation: “In 2025, we took strategic actions to set the Company up for long term growth… These efforts, coupled with improved margins, set Senseonics up for continued strong performance this year and beyond.”2021
Brian Hansen, Chief Commercial Officer, noted plans for $12-15 million in DTC spending, even distribution throughout the year, and expansion of the Eon Care network to 100 providers. He aims to double the U.S. patient base again in 2026 through renewals, new starts, and pump integrations.21
2026 Guidance
Senseonics projects full-year global net revenue of $58 million to $62 million, implying 65% to 76% growth. Gross margins are expected to approximate 50%, reflecting the full transition from Ascensia, DTC campaigns, and international expansion.1820
Pipeline advancements include Gemini launch in 2027 and Freedom in 2028, positioning Senseonics for sustained growth in the CGM market.
